Early Blood Flow Shifts Track Cancer Drug Response
A preclinical rat study used integrated optical monitoring to detect physiological changes in breast tumors before caliper-measured shrinkage appeared.
Updated on Nov. 3, 2026 in Cancer
Researchers using integrated diffuse reflectance and correlation spectroscopy tracked tumor physiology in a rat breast cancer model after a single dose of cyclophosphamide. Blood flow and metabolic rate rose on day 11, before tumor volume reduction was detected on day 12.
Why it matters
The findings suggest optical monitoring could reveal treatment effects earlier than conventional size measurements in preclinical cancer research. The results are limited to a rat model and do not establish clinical use in patients.
The study compared treated and untreated tumors using daily tissue oxygen saturation, blood flow, and metabolic rate measurements. Its statistical significance threshold was p < 0.05, and the reported ratio shift was seen in seven of eight treated animals with late observations.
The details
Researchers gave treated tumors a single dose of cyclophosphamide on day 9 and compared them with untreated controls. Blood flow and metabolic rate rose before caliper measurements detected any reduction in tumor volume.
Timeline
Day 9: Single dose of cyclophosphamide administered to treated tumors.
Day 11: Relative blood flow index and metabolic rate of oxygen rose in treated tumors.
Day 12: Tumor volume reduction detected by caliper measurements.
Health Landscape
The study extends the use of integrated diffuse reflectance and correlation spectroscopy, a noninvasive optical approach, from tissue characterization to longitudinal tracking of chemotherapy response. It remains a preclinical result and does not yet alter standard clinical monitoring of cyclophosphamide.
Current findings apply only to a rat model, so no change in patient monitoring or treatment decisions follows yet. Any future clinical use would depend on human studies confirming the early optical signal.
The takeaway
Early physiological changes can precede visible tumor shrinkage, which may matter for how treatment response is measured in research. Readers should treat these preclinical findings as early-stage evidence rather than a clinical guideline.
Further reading
For more on how cancer treatments are studied and tracked, explore the Cancer section.
Source note: This article includes information reported by Nature.
